Industry Briefs: Apr. 16, 2012
A roundup of additional company and people news from pharmaceutical and biopharmaceutical companies, their suppliers, and contract-service providers.
Company News
AMRI and Biota have agreed to develop and manufacture the influenza antiviral CS8958 (laninamivir), a second-generation, long-acting neuraminidase inhibitor. Read More
Evans Analytical Group (EAG) has acquired PTRL West and PTRL Europe. Read More
Nascent and Catalent Pharma Solutions have formed a product-development agreement for a Nascent antibody drug candidate. Read More
Pharmatek has added to its liquid encapsulation capabilities. Read More
Q Laboratories has completed construction on its 5000-ft2 microbiology research and development laboratory.
Shire has agreed to acquire Pervasis Therapeutics and related endothelial cell technology. Read More
Vanda Pharmaceuticals has acquired the rights to an NK-1 receptor antagonist from Eli Lilly. Read More
People News
Hospira has named John B. Elliot senior vice-president of operations. Read More
Penn Pharma has appointed Jerome Detreille as senior director of new business development. Read More
Michael A. Griffith has been appointed to Repligen’s board of directors.
Drug Solutions Podcast: Novel Drug Delivery Approaches: Refining AAV Vector Deliveries
May 30th 2025In this podcast episode, we discuss novel approaches to drug delivery, specifically regarding adeno-associated virus (AAV) vectors, as viewed by two industry experts who recently exhibited at the annual ASGCT meeting.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
